A Purdue Research Park-based plant biotech company and a fully-owned subsidiary of G+FLAS Life Sciences, South Korea-based CRISPR genome engineering company, creating 10-billion-people-feeding crops and plant-made pharmaceuticals.
A Purdue Research Park-based plant biotech company and a fully-owned subsidiary of G+FLAS Life Sciences, South Korea-based CRISPR genome engineering company, creating 10-billion-people-feeding crops and plant-made pharmaceuticals.
Using our proprietary tool box of CRISPR/Cas genome editing enzymes,
we develop novel traits in tomato, lettuce, soybean, and corn.
We develop the DNA-free genome editing technology for human nutrition and health.
Supports cloning and expression of target single guide RNAs (sgRNAs) for marmalian genome modification (organic editing) of CRISPR/Cas9 technology.
VIEW MORESupports cloning and expression of target single guide RNAs (sgRNAs) for marmalian genome modification (organic editing) of CRISPR/Cas9 technology.
VIEW MORESupports cloning and expression of target single guide RNAs (sgRNAs) for marmalian genome modification (organic editing) of CRISPR/Cas9 technology.
VIEW MORESample A C-terminal nuclear-localization signal (NLS) modified for use in CRISPR/Cas9 gene editing experiments as a Cas9 recombinant protein derived from Streptococcus pyogenes.
VIEW MOREG+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents
Feb. 24. 2021G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents
Feb. 24. 2021G+FLAS Life Sciences is applying CRISPR technology to develop research tools and reagents
Feb. 24. 2021